Founded some 20 years ago, MorphoSys is today one of the world's leading biotechnology companies. From a pure antibody platform enterprise, MorphoSys has matured into a renowned biopharmaceutical company with a rich pipeline of future therapeutic antibody products and a sustainable dual therapeutic business model. The Company’s aim is to continue pushing the boundaries of antibody generation in the industry – to engineer the medicines of tomorrow.
A new initiative through which MorphoSys provides innovation capital to promising start-ups.
MorphoSys recently published its 2012 Annual Report and the Online Magazine with additional information.
MorphoSys latest antibody platform Ylanthia now commercially available for partners.